Mark P. Colonnese

Mark has been a senior executive in the pharmaceutical and biotech industries for over thirty years. He has been successful in raising nearly $1 billion in public (including IPOs) and private financings. Most recently he served as Executive Vice President and Chief Financial Officer of Aviragen Therapeutics from November 2015 until its merger with Vaxart Inc. in February 2018. Previously, he has served as the Chief Financial Officer of several public and private biotech and diagnostic companies. He has also held executive and management positions at Schering-Plough Corporation and served on the Board of Directors of Endeavor Pharmaceuticals, Inc. He currently is a Board Director of Bio-Path Holdings, Inc. a Nasdaq-listed biotech company. He holds an MBA from Fairleigh Dickinson University and a BS magna cum laude in Accounting from Ithaca College.